Opendata, web and dolomites

PFS SIGNED

A cost- energy-efficient treatment technology to remove pharmaceutical pollutants from water

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PFS project word cloud

Explore the words cloud of the PFS project. It provides you a very rough idea of what is the project "PFS" about.

wastewater    native    globally    levels    upcoming    threats    energy    100bn    serious    validate    easily    brings    legislation    organic    enzyme    water    compact    efficient    trial    200    2015    medicines    purification    market    markets    ph    pharem    first    pfs    veterinary    run    removing    plants    validated    patented    filtration    roll    drinking    solution    therapeutic    modified    active    compounds    bisphenol    urban    feasibility    times    counter    installed    temperature    requested    contribution    biological    infrastructure    synthetic    enzymes    total    industrialize    2020    commercial    day    public    size    pollutants    07m    ec    health    yearly    revenue    natural    removal    hormone    biotech    pharmaceuticals    stability    investments    treatment    deploy    found    successful    modern    designed    resistant    34m    chemicals    prescription    25bn    facilities    drugs    posing    antibiotics    prepare    litres    supply    alternative    widely    disruptors    mandatory   

Project "PFS" data sheet

The following table provides information about the project.

Coordinator
PHAREM BIOTECH AB 

Organization address
address: LEVERTINSGATAN 30-1202
city: UPPSALA
postcode: 754 30
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Project website https://www.pharem.se/wastewater-2/
 Total cost 2˙962˙500 €
 EC max contribution 2˙073˙750 € (70%)
 Programme 1. H2020-EU.3.5. (SOCIETAL CHALLENGES - Climate action, Environment, Resource Efficiency and Raw Materials)
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2018
 Duration (year-month-day) from 2018-03-01   to  2020-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PHAREM BIOTECH AB SE (UPPSALA) coordinator 2˙073˙750.00

Map

Leaflet | Map data © OpenStreetMap contributors, CC-BY-SA, Imagery © Mapbox

 Project objective

Widely used pharmaceuticals (synthetic or natural chemicals found in prescription medicines, over-the-counter therapeutic drugs & veterinary drugs) are finding their way into the drinking water supply via wastewater treatment facilities, posing serious threats to public health globally. The problem is that modern wastewater treatment facilities are not designed for effective removal of pharmaceuticals or similar organic compounds. Upcoming EU legislation will make such removal mandatory. Pharem Biotech brings to market PFS—the first patented enzyme-carrying filtration system capable of removing a large range of organic pollutants (pharmaceuticals and other biological active compounds such as bisphenol A, antibiotics, hormone disruptors, etc.). PFS is a filtration solution that can be easily installed at most of wastewater treatment facilities. Its compact size makes it particularly useful for urban wastewater treatment plants. PFS is based on modified enzymes which are 200 times more effective than native enzymes, resistant to low temperature, resistant to low pH and with high levels of stability and activity. Compared to alternative purification methods, PFS is very cost-efficient, and requires no energy to run. As the total EU yearly investments in its wastewater treatment facilities and related infrastructure are expected to reach €25bn per year in 2015-2020, Pharem Biotech is addressing the market of 70,000 facilities in EU processing 100bn litres of water per day in total. During a successful Phase 1 project, Pharem Biotech validated the market and commercial feasibility of PFS, and selected the trial cases to validate the technology as well as key target markets to approach. In this Phase 2 project Pharem Biotech will industrialize PFS, validate it in trial cases and prepare for commercial roll out with the objective is to deploy 50 PFS systems before 2020 and reach revenue of €34m. The requested EC contribution is €2.07m.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PFS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PFS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.5.;H2020-EU.2.3.1.)

EPIC (2017)

Environmentally Friendly Recycled Plastic Floors in Containers

Read More  

ProTreaT (2015)

FEASIBILITY ASSESSMENT OF THE GREEN “ProTreaT” TECHNOLOGY FOR PROTEIN-BASED, NATURAL REMOVAL OF HEAVY METALS FROM WATER AND WASTEWATER

Read More  

PBTech (2016)

Combined Plasma Biotrickling system for treating industrial VOC emissions

Read More